Investors sold shares of Bristol-Myers Squibb Co. (NYSE:BMY) on strength during trading hours on Thursday. $42.86 million flowed into the stock on the tick-up and $63.43 million flowed out of the stock on the tick-down, for a money net flow of $20.57 million out of the stock. Of all stocks tracked, Bristol-Myers Squibb had the 22nd highest net out-flow for the day. Bristol-Myers Squibb traded up $0.52 for the day and closed at $75.32

A number of equities analysts recently issued reports on BMY shares. Deutsche Bank AG reaffirmed a “hold” rating on shares of Bristol-Myers Squibb in a research report on Wednesday, June 15th. Credit Suisse Group AG reaffirmed an “overweight” rating on shares of Bristol-Myers Squibb in a research report on Tuesday, April 26th. Vetr raised shares of Bristol-Myers Squibb from a “strong sell” rating to a “sell” rating and set a $64.94 target price on the stock in a research report on Monday, April 25th. Argus reaffirmed a “buy” rating on shares of Bristol-Myers Squibb in a research report on Friday, May 13th. Finally, Zacks Investment Research lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, July 11th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $74.98.

The firm has a 50 day moving average of $74.20 and a 200 day moving average of $68.57. The stock has a market capitalization of $125.85 billion and a PE ratio of 44.05.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings results on Thursday, July 28th. The biopharmaceutical company reported $0.69 EPS for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.03. The company earned $4.90 billion during the quarter, compared to the consensus estimate of $4.60 billion. The firm’s revenue for the quarter was up 17.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.53 EPS. Equities analysts anticipate that Bristol-Myers Squibb Co. will post $2.64 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, November 1st. Investors of record on Friday, October 7th will be given a $0.38 dividend. This represents a $1.52 dividend on an annualized basis and a dividend yield of 2.02%. The ex-dividend date of this dividend is Wednesday, October 5th.

In related news, Director Lamberto Andreotti sold 23,200 shares of the firm’s stock in a transaction dated Friday, July 8th. The stock was sold at an average price of $74.45, for a total value of $1,727,240.00. Following the sale, the director now directly owns 380,099 shares of the company’s stock, valued at $28,298,370.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Sandra Leung sold 72,544 shares of the firm’s stock in a transaction dated Friday, May 6th. The shares were sold at an average price of $70.39, for a total value of $5,106,372.16. Following the completion of the sale, the executive vice president now directly owns 444,507 shares in the company, valued at $31,288,847.73. The disclosure for this sale can be found here.

Other hedge funds have added to or reduced their stakes in the company. Philadelphia Trust Co. raised its stake in Bristol-Myers Squibb by 0.5% in the fourth quarter. Philadelphia Trust Co. now owns 20,364 shares of the biopharmaceutical company’s stock valued at $1,365,000 after buying an additional 100 shares during the period. Boltwood Capital Management raised its stake in Bristol-Myers Squibb by 1.3% in the fourth quarter. Boltwood Capital Management now owns 15,540 shares of the biopharmaceutical company’s stock valued at $1,069,000 after buying an additional 200 shares during the period. Wellington Shields & Co. LLC raised its stake in Bristol-Myers Squibb by 0.5% in the fourth quarter. Wellington Shields & Co. LLC now owns 52,336 shares of the biopharmaceutical company’s stock valued at $3,600,000 after buying an additional 270 shares during the period. Pekin Singer Strauss Asset Management IL raised its stake in Bristol-Myers Squibb by 1.0% in the fourth quarter. Pekin Singer Strauss Asset Management IL now owns 33,948 shares of the biopharmaceutical company’s stock valued at $2,335,000 after buying an additional 330 shares during the period. Finally, Garcia Hamilton & Associates LP DE raised its stake in Bristol-Myers Squibb by 1.2% in the fourth quarter. Garcia Hamilton & Associates LP DE now owns 29,495 shares of the biopharmaceutical company’s stock valued at $2,029,000 after buying an additional 358 shares during the period.

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company operates in BioPharmaceuticals segment. Its pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes (involving recombinant deoxyribonucleic acid (DNA) technology) called biologics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.